Metabolic dysfunction and inflammatory disease: the role of stromal fibroblasts.

Publisher: Published by Blackwell Pub. on behalf of the Federation of European Biochemical Societies Country of Publication: England NLM ID: 101229646 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1742-4658 (Electronic) Linking ISSN: 1742464X NLM ISO Abbreviation: FEBS J Subsets: MEDLINE

Original Publication: Oxford, UK : Published by Blackwell Pub. on behalf of the Federation of European Biochemical Societies, c2005-

Fibroblasts/*metabolism ; Inflammation/*genetics ; Mesenchymal Stem Cells/*metabolism ; Metabolic Diseases/*genetics; Cellular Microenvironment/genetics ; Fibroblasts/pathology ; Heart Diseases/genetics ; Heart Diseases/metabolism ; Humans ; Inflammation/metabolism ; Inflammation/pathology ; Liver Diseases/genetics ; Liver Diseases/metabolism ; Mesenchymal Stem Cells/pathology ; Metabolic Diseases/metabolism ; Metabolic Diseases/pathology ; Pulmonary Fibrosis/genetics ; Pulmonary Fibrosis/metabolism ; Renal Insufficiency, Chronic/genetics ; Renal Insufficiency, Chronic/metabolism

Mesenchymal stromal fibroblasts have emerged as key mediators of the inflammatory response and drivers of localised inflammation, in part through their interactions with resident and circulating immune cells at inflammatory sites. As such, they have been implicated in a number of chronic inflammatory conditions as well as in tumour progression through modifying the microenvironment. The connection between metabolic changes and altered phenotype of fibroblasts in inflammatory microenvironments has clear implications for our understanding of how chronic inflammation is regulated and for the development of new anti-inflammatory therapeutics. In this review, we consider the evidence that changes to fibroblast metabolic state underpin chronic inflammation. We examine recent research on fibroblast metabolism in inflammatory microenvironments and consider their involvement in inflammation, providing insight into the role of fibroblasts and metabolism in mediating inflammatory disease progression namely cancer, arthritis and fibrotic disorders including chronic kidney disease, pulmonary fibrosis, heart disease and liver disease.
(© 2020 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)

Br J Pharmacol. 2017 May;174(9):893-908. (PMID: 28239846)
Int J Biol Sci. 2018 Jan 11;14(1):100-110. (PMID: 29483829)
Cell Cycle. 2012 May 1;11(9):1680-96. (PMID: 22510571)
Cell Cycle. 2011 Jun 1;10(11):1772-83. (PMID: 21558814)
Nat Commun. 2016 Oct 11;7:13050. (PMID: 27725631)
Oncol Lett. 2019 Nov;18(5):4645-4650. (PMID: 31611973)
Immunol Rev. 2010 Jan;233(1):233-55. (PMID: 20193003)
Arthritis Res Ther. 2017 Apr 11;19(1):76. (PMID: 28399896)
Virchows Arch. 2005 Feb;446(2):164-76. (PMID: 15609048)
J Biol Chem. 2016 Dec 30;291(53):27239-27251. (PMID: 27836973)
Arthritis Res Ther. 2005;7(3):R536-44. (PMID: 15899040)
Annu Rev Pathol. 2010;5:99-118. (PMID: 20078217)
Nat Commun. 2013;4:2823. (PMID: 24264436)
Sci Rep. 2018 Aug 14;8(1):12148. (PMID: 30108296)
J Immunol. 2001 Feb 15;166(4):2270-5. (PMID: 11160281)
Front Biosci. 2002 Sep 01;7:d1899-914. (PMID: 12161342)
Oncotarget. 2017 May 25;8(34):57813-57825. (PMID: 28915713)
Mol Cancer Ther. 2008 Jan;7(1):110-20. (PMID: 18202014)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Biomed Res Int. 2018 Jun 5;2018:6075403. (PMID: 29967776)
Cancer Immunol Res. 2018 Dec;6(12):1472-1485. (PMID: 30266714)
Oncogene. 2019 May;38(19):3681-3695. (PMID: 30664688)
Cancer Res. 2006 Jan 15;66(2):794-802. (PMID: 16424011)
Cell Cycle. 2012 Apr 1;11(7):1383-92. (PMID: 22421146)
Ann Rheum Dis. 2016 Dec;75(12):2192-2200. (PMID: 27013493)
J Cell Biol. 2017 Nov 6;216(11):3799-3816. (PMID: 29021221)
Oncogenesis. 2016 Feb 22;5:e198. (PMID: 26900950)
Immun Ageing. 2019 Nov 5;16:29. (PMID: 31708994)
Scand J Rheumatol. 2017 Mar;46(2):160-161. (PMID: 27098118)
PLoS Biol. 2010 Oct 19;8(10):e1000514. (PMID: 21049082)
Am J Respir Crit Care Med. 2015 Dec 15;192(12):1462-74. (PMID: 26284610)
Sci Rep. 2017 Jun 14;7(1):3451. (PMID: 28615667)
J Thorac Dis. 2014 Oct;6(10):1458-68. (PMID: 25364523)
Cancer Res. 2005 Oct 1;65(19):8887-95. (PMID: 16204060)
Cancer Discov. 2019 Aug;9(8):1102-1123. (PMID: 31197017)
Nat Commun. 2018 Mar 5;9(1):948. (PMID: 29507342)
Inflamm Res. 2016 Oct;65(10):815-25. (PMID: 27342824)
Antioxid Redox Signal. 2017 Mar 20;26(9):462-485. (PMID: 27228792)
Cell Rep. 2016 May 10;15(6):1161-74. (PMID: 27134168)
Int J Mol Sci. 2019 Apr 07;20(7):. (PMID: 30959975)
Curr Biol. 2016 Mar 21;26(6):755-65. (PMID: 26948875)
Hepatology. 2013 Jan;57(1):339-50. (PMID: 22961591)
Nat Metab. 2019 Jan;1(1):147-157. (PMID: 32694814)
BMC Cardiovasc Disord. 2017 Mar 23;17(1):88. (PMID: 28335740)
J Clin Invest. 2012 Sep;122(9):3127-44. (PMID: 22922255)
Eur Rev Med Pharmacol Sci. 2018 Jul;22(13):4243-4251. (PMID: 30024614)
Br J Pharmacol. 2008 Mar;153 Suppl 1:S241-6. (PMID: 17965753)
Curr Rheumatol Rep. 2017 Aug;19(8):45. (PMID: 28718060)
J Clin Invest. 2005 Feb;115(2):209-18. (PMID: 15690074)
J Hematol Oncol. 2019 Aug 28;12(1):86. (PMID: 31462327)
Arthritis Rheumatol. 2020 Apr;72(4):609-619. (PMID: 31682073)
Sci Rep. 2017 Feb 22;7:43165. (PMID: 28225071)
Nat Chem Biol. 2017 Jan;13(1):38-45. (PMID: 27820799)
Cell Cycle. 2011 Dec 1;10(23):4065-73. (PMID: 22129993)
Kidney Int. 2011 May;79(9):944-56. (PMID: 21307839)
J Clin Invest. 2008 Nov;118(11):3537-45. (PMID: 18982160)
Arthritis Rheum. 2011 Jun;63(6):1626-36. (PMID: 21337319)
J Cell Physiol. 2010 Nov;225(3):631-7. (PMID: 20635395)
Oncogene. 2014 Jan 2;33(1):97-107. (PMID: 23208491)
Cancer Res. 2013 May 15;73(10):3007-18. (PMID: 23514705)
BMC Syst Biol. 2010 May 06;4:58. (PMID: 20459610)
Nat Rev Cancer. 2020 Mar;20(3):174-186. (PMID: 31980749)
Nature. 2013 Jun 6;498(7452):109-12. (PMID: 23685455)
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3414-9. (PMID: 19218429)
J Mol Med (Berl). 2016 Feb;94(2):155-71. (PMID: 26099350)
Mol Aspects Med. 2019 Feb;65:100-109. (PMID: 30385174)
Cancer Lett. 2016 Sep 28;380(1):272-80. (PMID: 26546872)
Lab Invest. 2019 Jun;99(6):777-792. (PMID: 30683902)
Cell Rep. 2015 Mar 3;10(8):1335-48. (PMID: 25732824)
J Cell Mol Med. 2018 May 28;:. (PMID: 29808534)
Best Pract Res Clin Rheumatol. 2008 Apr;22(2):239-52. (PMID: 18455682)
Joint Bone Spine. 2016 Dec;83(6):707-713. (PMID: 27133762)
Clin Cancer Res. 2002 Sep;8(9):2912-23. (PMID: 12231536)
J Immunol. 1999 May 15;162(10):5949-56. (PMID: 10229832)
J Pathol. 2011 Apr;223(5):604-17. (PMID: 21341274)
Cell Death Dis. 2016 Dec 1;7(12):e2495. (PMID: 27906172)
Nat Rev Mol Cell Biol. 2002 May;3(5):349-63. (PMID: 11988769)
Cancers (Basel). 2019 Jun 04;11(6):. (PMID: 31167399)
Nat Rev Immunol. 2010 Oct;10(10):712-23. (PMID: 20865019)
Arthritis Rheum. 2008 Dec;58(12):3684-92. (PMID: 19035519)
Arthritis Rheumatol. 2016 Jul;68(7):1614-26. (PMID: 26815411)
Front Immunol. 2015 Nov 09;6:569. (PMID: 26617604)
Cell Commun Signal. 2018 Nov 23;16(1):89. (PMID: 30470231)
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16472-7. (PMID: 17060621)
J Immunol. 1992 Jul 15;149(2):722-7. (PMID: 1624809)
Nature. 2019 Jun;570(7760):246-251. (PMID: 31142839)
Cancer Res. 2003 Dec 15;63(24):8827-36. (PMID: 14695199)
Am J Respir Cell Mol Biol. 2018 Mar;58(3):378-390. (PMID: 29019707)
Cell Metab. 2019 Dec 3;30(6):1055-1074.e8. (PMID: 31708446)
Cell Metab. 2016 Nov 8;24(5):685-700. (PMID: 27829138)
J Proteome Res. 2015 Apr 3;14(4):1854-71. (PMID: 25690941)

FS/12/38/29640 United Kingdom BHF_ British Heart Foundation; MR/N011775/1 United Kingdom MRC_ Medical Research Council; 21530 United Kingdom VAC_ Versus Arthritis; PG/15/105/31906 United Kingdom BHF_ British Heart Foundation; 21812 United Kingdom VAC_ Versus Arthritis; MR/P021220/1 United Kingdom MRC_ Medical Research Council; MR/T016736/1 United Kingdom MRC_ Medical Research Council

Keywords: fibroblasts; inflammation; innate immune cells; metabolism

Date Created: 20201130 Date Completed: 20211014 Latest Revision: 20240320

20240320

PMC8518940

10.1111/febs.15644

33251764